Literature DB >> 11472044

Lipoprotein (a) level and mortality in patients with critical lower limb ischaemia.

S W Cheng1, A C Ting.   

Abstract

OBJECTIVE: to investigate if serum lipoprotein (a) level is a predictor of survival in patients with lower limb atherosclerotic occlusive disease.
DESIGN: prospective follow up study.
METHODS: demographic, biochemical and disease variables were collected prospectively in 441 patients with lower limb arterial occlusive disease. Survival data were obtained at a mean follow up of 44 months, and significant risk factors identified by the life table method and multivariate Cox regression analysis.
RESULTS: the cumulative survival for all patients at three and five years was 79% and 63%. Lipoprotein (a) level was the only significant independent biochemical predictor for all deaths and cardiorespiratory deaths on multivariate analysis, along with age, diabetes mellitus, renal impairment, cardiac diseases and major amputation. An elevated Lipoprotein(a) level of >24 mg/dl incurred a 107% and 45% increase in mortality at three and five years respectively. The higher mortality associated with elevated Lipoprotein (a) was particularly evident in patients with critical ischemia, in whom three and five year survival was reduced from 85% to 63% and 67% to 53% (p=0.0064). In claudicants a survival discrepancy was manifested only after five years (73% vs 62%), and the overall association did not reach statistic significance (p=0.52).
CONCLUSIONS: lipoprotein (a) level is a reliable biochemical marker for survival in patients with critical ischemia where traditional atherosclerosis risk factors were prevalent. Copyright 2001 Harcourt Publishers Limited.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11472044     DOI: 10.1053/ejvs.2001.1431

Source DB:  PubMed          Journal:  Eur J Vasc Endovasc Surg        ISSN: 1078-5884            Impact factor:   7.069


  4 in total

1.  Coronary Artery Disease Severity and Cardiovascular Biomarkers in Patients with Peripheral Artery Disease.

Authors:  Hiroyuki Hikita; Takatoshi Shigeta; Shigeki Kimura; Atsushi Takahashi; Mitsuaki Isobe
Journal:  Int J Angiol       Date:  2015-06-26

2.  Epidemiological aspects of atherosclerosis in patients treated for acute atherothrombosis of extremity arteries.

Authors:  Nedzad Rustempasic; Dragan Totic; Muhamed Djedovic; Medzida Rustempasic; Nada Malesic
Journal:  Med Arch       Date:  2014-10-15

Review 3.  Lipoprotein(a): An independent, genetic, and causal factor for cardiovascular disease and acute myocardial infarction.

Authors:  Enas A Enas; Basil Varkey; T S Dharmarajan; Guillaume Pare; Vinay K Bahl
Journal:  Indian Heart J       Date:  2019-03-20

4.  Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome: Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial.

Authors:  Gregory G Schwartz; Philippe Gabriel Steg; Michael Szarek; Vera A Bittner; Rafael Diaz; Shaun G Goodman; Yong-Un Kim; J Wouter Jukema; Robert Pordy; Matthew T Roe; Harvey D White; Deepak L Bhatt
Journal:  Circulation       Date:  2020-03-29       Impact factor: 29.690

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.